These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11816020)

  • 1. The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer.
    Pelger RC; Lycklama A Nijeholt GA; Zwinderman AH; Hamdy NA
    Prostate; 2002 Feb; 50(2):119-24. PubMed ID: 11816020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival.
    Pelger RC; Lycklama A Nijeholt Ga; Zwinderman AH; Hamdy NA
    Cancer; 2002 May; 94(10):2596-601. PubMed ID: 12173326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma.
    Pelger RC; Lycklama A Nijeholt GA; Zwinderman AH; Papapoulos SE; Hamdy NA
    J Urol; 1996 Jul; 156(1):122-6. PubMed ID: 8648772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
    Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A
    Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
    Taue R; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of disseminated prostate cancer with estramustine.
    Rosenthal MA; Raghavan D; Stuart-Harris R; Ackland S; Grygiel J
    Aust N Z J Surg; 1992 Nov; 62(11):871-3. PubMed ID: 20169706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.
    Iversen P; Rasmussen F; Asmussen C; Christensen IJ; Eickhoff J; Klarskov P; Larsen E; Mogensen P; Mommsen S; Rosenkilde P
    J Urol; 1997 Mar; 157(3):929-34. PubMed ID: 9072602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular changes in prostatic carcinoma after treatment with orchidectomy, estramustine phosphate and medroxyprogesterone acetate.
    Tomic R; Angström T; Ljungberg B
    Scand J Urol Nephrol; 1997 Jun; 31(3):255-8. PubMed ID: 9249888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy.
    Nakashima J; Ozu C; Nishiyama T; Oya M; Ohigashi T; Asakura H; Tachibana M; Murai M
    Urology; 2000 Nov; 56(5):843-7. PubMed ID: 11068314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.
    Boccardo F; Decensi A; Guarneri D; Martorana G; Giberti C; Giuliani L
    Cancer Chemother Pharmacol; 1988; 22(2):172-4. PubMed ID: 3409448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined androgen blockade.
    Crawford ED
    Eur Urol; 1996; 29 Suppl 2():54-61. PubMed ID: 8717465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.